Androgen-deprivation therapy can be essential prostate-cancer treatment. It can also reduce muscle, increase fat, lower aerobic capacity and deepen fatigue. Exercise is sometimes offered as generic wellness advice. In this setting, the evidence supports something more specific: a structured part of supportive care. The goal is not athletic performance. It is keeping people stronger and more independent while the hormonal environment changes.
Evidence at a glance
- Studied population: men receiving androgen-deprivation therapy, often without unstable bone metastases or major exercise contraindications.
- Programs studied: supervised aerobic and resistance training, usually two or three sessions weekly for several months.
- Meaningful benefit: better strength, fitness, fatigue and preservation of lean mass.
- Negative finding: exercise has not consistently improved overall quality-of-life scores, PSA or lipid levels.
- Cancer control: these trials evaluate treatment side effects—not whether exercise controls prostate cancer.
What the trials actually did
One randomized trial enrolled men newly beginning ADT. The intervention was supervised combined aerobic and resistance exercise for 60 minutes twice weekly for three months, followed by three months of self-directed activity. At three months, exercise prevented declines in peak oxygen uptake and produced a 4.5-point between-group improvement on a validated fatigue scale. Strength, fitness and aspects of quality of life improved, although supervised support was not indefinite.
Another trial of 57 men who had already received androgen suppression for more than two months compared 12 weeks of combined resistance and aerobic training with usual care. Exercise reversed muscle loss, improved strength and reduced fatigue. A larger year-long study of 163 men found that impact-plus-resistance training reduced fatigue by roughly five points at six and twelve months; aerobic-plus-resistance training also helped by twelve months.
The broader evidence remains appropriately modest. A meta-analysis of 30 randomized trials found better fitness, strength and body composition with resistance or combined training, but no detectable change in PSA or lipids. ASCO’s exercise guideline recommends aerobic and resistance exercise during active cancer treatment to mitigate side effects, while acknowledging variable programs and limited long-term data.
Safety changes the prescription
The research schedules above describe protocols, not a personal prescription. Bone metastases, osteoporosis, neuropathy, falls, anemia, cardiac disease and recent surgery can change which movements are safe. Impact loading may be inappropriate when fracture risk is high. A cancer-rehabilitation clinician or exercise physiologist can adapt resistance, balance and aerobic work around disease location and baseline function.
Questions for the care team
- Do I need bone-density or fracture-risk assessment before starting?
- Would supervised resistance training help preserve muscle and daily function?
- Are there bone metastases or cardiovascular issues that require exercise modifications?
- Which outcomes should we track—fatigue, chair rise, walking capacity, strength or body composition?
Explore the Missing Script evidence library, and follow the podcast, coming soon. This article is educational and does not replace individualized medical care.
